VERTEX PHARMACEUTICALS INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 409.1 USD | +1.64% |
|
+4.27% | +0.66% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
2024-05-15
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
402.5
USD
Average target price
460.7
USD
Spread / Average Target
+14.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.66% | 104B | |
| +9.40% | 106B | |
| +6.72% | 23.25B | |
| -13.21% | 22.5B | |
| -6.64% | 18.7B | |
| -37.26% | 17.95B | |
| -11.85% | 16.99B | |
| +8.41% | 14.26B | |
| +37.84% | 12.76B | |
| +329.40% | 8.62B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $440 From $400, Keeps Hold Rating